West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates

Core Viewpoint - West Pharmaceutical Services reported quarterly earnings of $1.82 per share, exceeding the Zacks Consensus Estimate of$ 1.75 per share, although down from $1.83 per share a year ago, indicating a 4% earnings surprise [1] Financial Performance - The company achieved revenues of$ 748.8 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.25%, compared to $732 million in the same quarter last year [2] - Over the last four quarters, West Pharmaceutical has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance and Outlook - West Pharmaceutical shares have declined approximately 1.6% since the beginning of the year, while the S&P 500 has gained 2.9% [3] - The company's current consensus EPS estimate for the upcoming quarter is$ 1.63 on revenues of $715.32 million, and for the current fiscal year, it is$ 7.44 on revenues of $3.03 billion [7] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, which may impact stock performance [8]